To report counterfeit medicines and suspicious vendors toll free : 0800 101 999

Directorate of Product Safety

NDA hosts 40th annual Pharmacovigilance centres' meeting

Uganda was the host of the 40th annual meeting of representatives of the National Pharmacovigilance Centres (NPC).The meeting was hosted by the National Drug Authority and held at Speke Resort Munyonyo, from 6th November to 10th November 2017. Uganda was chosen to host this meeting because of its remarkable progress in the safety of medicines in the African continent.

May 6th - 10th 2018

Harvest money expo Nambole

NDA officers dispensing information to the public at the Harvest Money expo at Nambole

February 17th 2018

The Secretary to the Authority and Directors engage with journalists from various media houses

"We got some preliminary results from the tests we did on the suspected Hep B vaccines and so far all results are good but inconclusive. We're working with World Health Organization (WHO) to get the conclusive results," Victoria Nambasa - acting Director Product Safety.

May 24th 2018

Pharmacovigilance training held in Hoima district.

World Health Organization (WHO) defines Pharmacovigilance as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. It is important to note that Uganda has a National Pharmacovigilance Center , under the National Drug Authority.

Updated List of Teratogenic Drugs (medicines with agents that can disturb the development of an embryo or fetus)

There are several teratogenic drugs which when used during pregnancy can disturb the development of the embryo or foetus by halting the pregnancy or producing congenital malformations (birth defects).

Follow this link to find a list of teratogenic drugs and our recommendation/s to pregnant mothers. Safe Drugs, Save Lives.

  News and Announcements
  • Recall of Valsartan a drug used in the treatment of high blood pressure Read more...
  • Risk of crystalization of Mannitol 20% iv solution Read more...
  • Risk of Drug interactions and side effects due to using Herbal remedies alongside anticancer treatment Read more...
  • Risk of hypersensitivity reaction in infants and children following administration of Nevirapine Read more...
  • Increased risk of ototoxicity following concomitant administration of Gentamicin And Furosemide... Read more...
  • Risk of Abortion and birth defects with fluconazole... Read more...
  • Previously unidentified potential risk of visual color distortions with Pregabalin... Read more...
  • Public Alert - Counterfeit Cancer Medicine (Sutent)... Read more...
  • Public Alert - Counterfeit Cancer Medicine (Avastin)... Read more...
  • Postinor2 Counterfeit Alert... Read more...

Word from the director

The Product Safety directorate ensures that all stakeholders, pharmaceutical service providers and the general public receive the right information on medicines.

The directorate also ensures that drug promotional materials are vetted, approved and monitored to ensure that misleading, biased and inaccurate information on medicines is not disseminated. It is also responsible for pharmacovigilance programs, adverse drug reactions reporting, clinical trials monitoring and hosting the National Pharmacovigilance Centre.

Contact NDA

<
0414-255665Product Safety
Whatsapp 0791415555.National Drug Authority
druginfo@nda.or.ugP. O Box 23096, Kampala, Uganda
psur@nda.or.ugPlot 19 Lumumba Avenue (opposite TWED plaza)
clinicaltrials@nda.or.ugTel: +256 417 788 100/1 +256 417 788 124 / 041 788 129
Email: ndaug@nda.or.ug